In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

Vizient released its Summer 2025 Spend Management Outlook forecasting a 3.35% increase in pharmaceutical prices in 2026 with healthcare providers seeing increased usage in GLP-1 therapies, specialty ...

A trial assessing a new daily pill for weight loss has shown that people taking the drug can shed kilos in weeks, potentially offering people with obesity a new and convenient alternative to jabs.

Hims & Hers Health is upgraded to a speculative Buy after a 20% drop, with growth potential in GLP-1 sales outweighing key ...

SHOPPING: Enter Hers , the company offering a streamlined and more accessible option - without insurance, appointments, and ...

Scientists comment on oral GLP-1 (Orforglipron) and weight loss from a phase 3 clinical trial. Dr Simon Cork, Senior Lecturer in Physiology, Anglia Ruskin University, said: ...

Lilly’s results from an obesity pill study didn’t perform as well as Wall Street expected. It resulted in lower weight loss ...

Study participants lost an average of 12.4 per cent of their body weight over 72 weeks. View on euronews ...

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque ...

Whatever your thoughts on weight-loss injections, their rise shows no signs of slowing. And now a Dubai restaurant has become ...

GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.